v3.26.1
COLLABORATIONS - Additional Information (Detail)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 21, 2023
performance_obligation
Jun. 30, 2026
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
performance_obligation
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
program
Jun. 30, 2025
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Contract with customer liability revenue recognized         $ (800) $ 13,000   $ 4,100 $ 41,100    
Research and development         413,134 323,621   $ 778,000 588,743    
Number of separate programs | program               11      
Deferred revenue   $ 4,014     4,014     $ 4,014     $ 4,845
Total revenues         1,290,948 773,689   2,458,123 1,367,878    
Collaborations                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenues         47,165 61,496   129,240 160,681    
Roche | License                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Transaction price   1,740,000     1,740,000     1,740,000      
Regeneron Pharmaceuticals                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenues         5,020 32,542   51,356 83,581    
Regeneron Pharmaceuticals | Research Services Obligation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue   $ 4,000     4,000     $ 4,000     $ 4,800
Vir Biotechnology, Inc. | Collaborations                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenues     $ 30,000       $ 30,000        
Inceptive Nucleics, Inc                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Collaboration agreement, initial research term   3 years                  
Collaboration agreement, right to terminate, written advance notice period   30 days                  
Purchase price   $ 15,000                  
Roche Collaboration and License Agreement                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Development costs, percentage responsible 40.00%                    
Profit and loss sharing percentage 50.00%                    
Number of performance obligations | performance_obligation 3                    
Roche Collaboration and License Agreement | Roche                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Development costs, percentage responsible 60.00%                    
Profit and loss sharing percentage 50.00%                    
Actual reimbursement of transactional price (as percent)               60.00%      
Transaction price   1,738,167     1,738,167     $ 1,738,167      
Remaining performance obligation   829,800     829,800     829,800      
Research and development         73,300 31,000   134,500 60,700    
Total revenues         41,888 18,267   77,529 35,323    
Global Strategic Collaboration | Regeneron Pharmaceuticals                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Number of performance obligations | performance_obligation       2              
Remaining performance obligation   28,200     28,200     28,200      
Research and development         12,200 12,500   23,200 31,500    
Upfront payment       $ 10,000              
Maximum royalties and commercial milestone payments upon potential product sale       $ 325,000              
Designated candidates, period after expiration of initial research term       2 years              
Maximum additional milestone payments to be receive upon achievement of certain criteria                   $ 100,000  
Maximum percentage of royalty payments                   20.00%  
Global Strategic Collaboration | Regeneron Pharmaceuticals | Maximum                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Collaborative arrangement milestone payments, per collaboration project                   $ 150,000  
Royalty rate                   20.00%  
Global Strategic Collaboration | Regeneron Pharmaceuticals | Funding At Program Initiation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential proceeds from collaboration arrangement                   $ 2,500  
Global Strategic Collaboration | Regeneron Pharmaceuticals | Funding At Lead Candidate Identification                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential proceeds from collaboration arrangement                   $ 2,500  
Global Strategic Collaboration | Regeneron Pharmaceuticals | C5 Monotherapy Obligation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Fixed consideration       $ 191,500              
Global Strategic Collaboration | Regeneron Pharmaceuticals | Research Services Obligation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Transaction price   $ 100,500     100,500     100,500      
Total revenues         $ (802) $ 12,957   $ 5,831 $ 26,767